Source: Annual Congress 2005 - Prognostic factors in lung cancer
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Zhou, Y. Li, J. Xu, O. Ming (Guangzhou, China). The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance. Eur Respir J 2005; 26: Suppl. 49, 3167

Member's Comments

No comment yet.

Related content which might interest you: Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002 p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 Studies on clinical significance and relationship with PI and gene protein expression of p16, Rb and Cyclin-D1 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Genotyping single-nucleotide polymorphisms (SNP) in ERCC1, XPD, XRCC1, XRCC3 and MDR-1 and CCND-1 genes for response and toxicity prediction in chemotherapy of non small cell lung cancer (NSCLC) Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006 Association of polymorphism of the human nm23-H1 gene (NME1) with susceptibility to and severity of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 The development of mutant P53 characterized by lung cancers contributes to their primary and acquired multi-drug resistance to chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019 The effect of new drug-resistance antisense gene on multidrug resistance mechanism of drug-resistant human small cell lung cancer cells Source: Eur Respir J 2007; 30: Suppl. 51, 715s Year: 2007 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule Source: Annual Congress 2009 - Pathogenesis of lung cancer Year: 2009 Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis Source: Eur Respir J 2002; 20: 703-709 Year: 2002